11Apr/14

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy … – The Pharma Letter


The Pharma Letter

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy
The Pharma Letter
It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, …

11Apr/14

FDA grants breakthrough therapy status for Celladon' heart failure treatment … – Pharmaceutical Business Review

FDA grants breakthrough therapy status for Celladon’ heart failure treatment
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Celladon’s lead product candidate, Mydicar, for reducing hospitalisations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb …
FDA Grants “Breakthrough Therapy” Status for Gene Therapy to reduce Systolic Next Big Future

all 2 news articles »